Imotec

Quick links to important sections

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Imotec

Quick Facts

Property Description
Active ingredient Formoterol fumarate dihydrate
Form Dry Powder for Inhalation, Nebulizer Solution
Pharmacological Class Long-Acting Beta Agonist (LABA), Bronchodilator
General Purpose Sustained maintenance of open airways
Origin Synthetic compound

Imotec is a pharmaceutical product designed to manage airway restriction, categorized as a bronchodilator medication. It is a synthetic, single-entity product containing the active ingredient Formoterol fumarate dihydrate, which is the core substance responsible for its therapeutic action.


What Type of Medicine is Imotec? (Identity and Classification)

Imotec belongs to the specific pharmacological class known as a Long-Acting Beta Agonist (LABA). As a beta2-adrenergic agonist, its primary function is to provide sustained relaxation of the muscle surrounding the air passages in the lungs. This classification determines the drug's role: Imotec is used for the ongoing, maintenance control of conditions characterized by chronic narrowing of the airways, rather than for sudden, emergency relief.


Composition and Delivery Form (Physical and Chemical Makeup)

The active substance in Imotec is the chemical compound Formoterol, a synthetic agent delivered directly to the lungs via the route of oral inhalation. It is typically available as either a dry powder in capsules intended for use with an inhaler device, or as an aqueous solution for use with a nebulizer. Formoterol is distinctive because it is a racemic mixture, chemically containing both the active (R,R)-enantiomer and the inactive (S,S)-enantiomer. The primary composition involves the Formoterol active ingredient combined with an inert base or vehicle, such as a lactose carrier powder or sterile water, for efficient respiratory delivery.


General Purpose and Action (High-Level Benefit)

The general purpose of Imotec is to provide sustained relief from the sensation of shortness of breath and chest tightness associated with chronic air flow restriction. This is achieved through its primary function: causing the relaxation of the airway muscles (bronchodilation). Formoterol combines both a rapid onset of action with a long duration, which characterizes its role in maintenance therapy. This property provides a sustained opening of the bronchial tubes, which is fundamental to supporting steady air exchange over a long period.

What side effects are possible with Imotec?

Possible Side Effects and Safety Information for Imotec

The safety profile for Imotec is compiled and presented by government regulatory bodies based on the frequency and severity of reported side effects, known as adverse reactions.

Adverse Reaction Categories

Adverse reactions are formally classified to show their relative likelihood, typically grouped by the affected System Organ Class (e.g., General disorders, Nervous system, Gastrointestinal disorders). The frequency categories used in regulatory documents are generally: Very Common (may affect more than 1 in 10 people), Common (may affect up to 1 in 10 people), Uncommon (may affect up to 1 in 100 people), Rare (may affect up to 1 in 1,000 people), and Very Rare (may affect up to 1 in 10,000 people).

Serious Adverse Reactions and Safety Surveillance

Serious adverse reactions are formally defined in official documents as any adverse event that is fatal, life-threatening, requires or prolongs inpatient hospitalization, results in persistent or significant disability, or is otherwise deemed medically significant. This classification ensures these events are monitored with the highest priority.

Safety is also monitored via post-marketing surveillance, which involves the continuous collection and evaluation of data after the medicine has been made available to a wider patient population. This ongoing process helps to identify rare or previously unknown reactions and assess the safety profile across population-specific groups, such as children versus adults, as specified in regulatory labels.

Overdose and Emergency Response

Overdose of Imotec (Formoterol) is strictly defined by regulatory documents as the result of excessive beta-adrenergic stimulation, which primarily affects the cardiovascular and nervous systems. This information is derived from official prescribing information and is not clinical advice.

Documented Overdose Manifestations

Excessive exposure may result in signs that are exaggerations of the drug’s intended effects, including:

  • Cardiovascular: Tachycardia (fast heart rate), palpitations, cardiac arrhythmias, angina pectoris (chest pain), and blood pressure changes (hypo- or hypertension).
  • Systemic/Metabolic: Tremor, nervousness, headache, dizziness, hypokalemia (low potassium), and hyperglycemia (high blood sugar).

Severe Outcomes and Emergency Action

Official regulatory documents warn that overdosage of Formoterol has been associated with clinically significant cardiovascular effects and documented fatal outcomes. Life-threatening paradoxical bronchospasm, characterized by immediate worsening of breathing, is also a reported risk and requires immediate discontinuation of the medication.

Mandatory Help-Seeking Triggers:

  • Call emergency services immediately (e.g., 911) if the person has collapsed, had a seizure, has severe trouble breathing, or is unable to be awakened.
  • Prompt medical attention is required if the usual regimen fails to maintain symptom control or if the patient needs to increase use of short-acting reliever medications.

Management Note

Treatment for overdose is described as symptomatic and supportive. Continuous cardiac monitoring is officially recommended. Regulatory labeling notes that there is no specific antidote known for Formoterol overdose.

Therapeutic Uses of Imotec

What Imotec Treats: Main Uses and Benefits

Imotec (formoterol) is commonly used for the long-term maintenance treatment of Chronic Obstructive Pulmonary Disease (COPD), including chronic bronchitis and emphysema. This application is relevant in conditions where symptoms related to physical discomfort, such as chronic shortness of breath and wheezing, create noticeable physiological strain. This therapy helps ease the overall symptom burden and supports improved day-to-day comfort, which supports consistent breathing comfort throughout the day and night.

The medication is generally considered relevant for managing symptoms that interfere with daily functioning in patients with persistent asthma in conjunction with other foundational controller therapies, and it is used for managing or reducing the onset of Exercise-Induced Bronchospasm (EIB). Imotec contributes to easing the impact of symptoms on routine activities and helps maintain a sense of stability when symptoms are more noticeable.

Summary: Support for Airflow Symptoms Symptom Type Condition Category Primary Benefit
Wheezing, Chest Tightness Chronic Obstructive Pulmonary Disease Contributes to easing the overall symptom load
Daily Dyspnea Persistent Asthma Assists with maintaining functional comfort
Activity-Triggered Symptoms Exercise-Induced Bronchospasm Assistance with preventing symptom onset

Regulatory References

  1. NIH MedlinePlus overview on formoterol

Eligibility and Restrictions for Use

The drug name Imotec is not found in official governmental drug regulatory databases. The following eligibility information is based on authoritative regulatory documents for Loperamide, the active substance in a commonly known anti-diarrheal medicine.

Eligibility Constraints

Population Status Official Restriction
Contraindicated Populations Children under 2 years of age; patients with known hypersensitivity (severe allergy) to the drug or its components.
Use Not Recommended Patients with acute dysentery (characterized by blood in stool and high fever); patients with acute ulcerative colitis; patients with specific forms of bacterial enterocolitis or pseudomembranous colitis (associated with broad-spectrum antibiotics).
Age-Related Rule Contraindicated for all pediatric patients under 2 years of age due to the risks of respiratory depression and serious cardiac adverse events.
Physiological/Clinical States Use must be avoided when inhibition of intestinal movement (peristalsis) is medically contraindicated (e.g., risk of ileus or toxic megacolon). Patients with hepatic impairment should use with caution.

Eligibility to use the medicine is strictly defined by the exclusion of patients with these contraindications and specific gastrointestinal conditions. Use is restricted to adults and children 2 years of age and older, but regulatory documents strongly warn that exceeding the recommended dose in any eligible patient increases the risk of serious, potentially fatal, cardiac adverse reactions.

What should I know about interactions with other medicines?

The official interaction profile of Imotec (formoterol) is defined by its role as an adrenergic agonist, which guides its pharmacodynamic interactions with several classes of medicinal products as documented in regulatory labeling.

Contraindicated and Restricted Combinations

Co-administration with other Long-Acting beta2-Agonists (LABAs), such as salmeterol or arformoterol, is formally restricted to avoid the risk of overdosage and clinically significant cardiovascular effects. Furthermore, Imotec is not indicated for use as monotherapy in the treatment of asthma without a concomitant long-term controller therapy, such as an inhaled corticosteroid.

Interactions Requiring Extreme Caution

Co-administration with Monoamine Oxidase Inhibitors (MAOIs), Tricyclic Antidepressants (TCAs), or drugs known to prolong the QTc interval must be approached with extreme caution. This restriction is due to the potential for these agents to potentiate the adrenergic effects of Imotec on the cardiovascular system.

Pharmacodynamic Potentiation and Antagonism

Beta-Blockers may inhibit the therapeutic bronchodilating effect and are documented to potentially induce severe bronchospasm. The use of Xanthine Derivatives, Systemic Steroids, or Non-Potassium Sparing Diuretics with Imotec may potentiate the risk of hypokalemia or lead to adverse electrocardiographic changes. The regular use of inhaled Short-Acting beta2-Agonists (SABAs) must be discontinued upon starting Imotec, reserving them only for acute, symptomatic relief. The official label also notes that systemic exposure to formoterol may increase in the patient population with severe hepatic impairment.

Mechanism of Action

Pharmacodynamic Mechanism: Ras-Raf-MEK-ERK Pathway

Imotec acts as a specific allosteric inhibitor of the Serine/threonine-protein kinases MEK1 and MEK2. These enzymes are central components of the intracellular Ras-Raf-MEK-ERK signaling pathway, which regulates fundamental cellular processes. By binding to an allosteric site on MEK1/2, Imotec induces a conformational change that prevents the upstream kinase (Raf) from activating MEK. This inhibition results in a downstream reduction in the phosphorylation of Extracellular-signal-regulated Kinase (ERK1/2). The resulting molecular cascade modifies the cellular signaling environment, leading to the slowing or arresting of cell cycle progression and growth in cell populations dependent on this pathway. This action modulates signaling driven by dysregulated pathway activity, thereby adjusting the overall cell population dynamics and contributing to the observed physiological adjustments.

Dosage and Administration Information

How to Use Imotec: Administration Guidelines

Imotec (Formoterol fumarate dihydrate) is intended solely for oral inhalation and is available in two dosage forms: as a dry powder capsule for use with a dedicated inhaler device, or as an aqueous solution for administration via a standard jet nebulizer. This medicine is classified as a long-term control agent and is not indicated for the relief of sudden, acute breathing difficulties.


Standard Dosage and Frequency

Use of Imotec follows established protocols based on the formulation:

Administration Goal Dosage Form Standard Regimen Maximum Daily Dose
Maintenance Dry Powder Capsule 12 mcg twice daily 24 mcg total
Maintenance Nebulizer Solution 20 mcg twice daily 40 mcg total

The maintenance regimen requires administration approximately every 12 hours (morning and evening). For the prevention of exercise-induced symptoms, the dry powder capsule is used on an as-needed basis, taken at least 15 minutes prior to the activity, with a restriction against taking additional doses for 12 hours.


Administration Requirements

Specific procedural conditions ensure proper delivery of the medication. The capsule formulation is placed into the designated device for inhalation and must not be swallowed whole. For the nebulizer solution, each single-dose vial must be administered immediately after opening using an air compressor-driven jet nebulizer; the contents should not be mixed with other medications within the nebulizer cup. Dosing guidelines also extend to the pediatric population, where the 12 mcg capsule is used for children 5 years of age and older for both maintenance and prevention.

Recent Clinical Evidence

Research evidence / Overview of Studies for Imotec (Formoterol)


Evidence for Maintenance Treatment of Chronic Obstructive Pulmonary Disease (COPD)

Research examining Formoterol for Chronic Obstructive Pulmonary Disease (COPD) includes several randomized controlled trials (RCTs) and systematic reviews. These studies were used in research exploring how symptoms change over time and were designed to observe changes in the respiratory health of adults diagnosed with moderate to severe COPD. Researchers specifically monitored outcomes related to physiological strain or stress like lung function measurements (such as FEV1) and outcomes describing episodic or acute changes like periods of worsening COPD symptoms, known as exacerbations.

Studies reported different measurements of lung function following the administration of Formoterol compared to the measurements observed when participants received an inactive substance (placebo). Findings describe patterns observed in the studies where research has explored whether there are differences in the time to first COPD exacerbation during the trial. Data for certain groups, such as patients with multiple other complex conditions (comorbidities), remain insufficient to draw broad conclusions about patterns in these specific populations.


Evidence for Maintenance Treatment of Persistent Asthma

Formoterol was evaluated in studies as an add-on therapy for persistent asthma, specifically in patients who were already using inhaled corticosteroids (ICS). This research primarily consisted of randomized controlled trials used in research exploring how symptoms change over time. The goal of these studies was to monitor patient-reported outcomes describing perceived discomfort related to asthma control and to monitor the occurrence of outcomes describing episodic or acute changes like severe asthma exacerbations.

Studies reported how symptoms evolved in the observed populations when Formoterol was added to the standard ICS treatment. These findings describe patterns observed in the studies related to outcomes reflecting daily functioning or activity level and research highlights changes measured during the study period in objective lung function tests. The research evidence base is primarily structured around its use with an ICS, and this distinction has been noted in official scientific reviews.


Evidence Gaps and Areas for Further Research

The available evidence studies contribute to the broader evidence landscape, but several areas remain uncertain. Comparative evidence is lacking in some contexts, and the sample sizes were modest for specific subgroups, meaning that the results apply only to the populations studied and not necessarily to all patients in all circumstances. Specifically, there is limited information for long-term outcomes regarding the durability of effects over many years of treatment, and research is continuing to explore the findings.

Key Studies & References

  1. Formoterol Inhalation: MedlinePlus Drug Information
  2. Efficacy and safety of formoterol in patients with stable chronic obstructive pulmonary disease: a systematic review and meta-analysis

Frequently Asked Questions (FAQ)

Common questions about Imotec (FAQ)

Q: How quickly should I expect to see an effect from Imotec?

A: Studies and official information indicate that Imotec (Formoterol) has a rapid onset of action. Its therapeutic effect, which involves relaxing the muscles around the airways, is reported in official documents as starting rapidly, often within a few minutes of inhalation. This rapid action is sustained, as the medication is intended for long-term maintenance.

Q: Does Imotec cause drowsiness or affect driving?

A: Official reports for Imotec indicate that dizziness and insomnia (difficulty sleeping) have been reported as common adverse reactions in clinical studies. Because of the potential for these effects, official labeling advises caution when using the medicine while performing tasks that require concentration, such as driving or operating heavy machinery.

Q: Can Imotec be taken long-term?

A: Imotec is indicated for long-term, twice-daily administration. It is specifically classified as a maintenance treatment for chronic airway conditions, intended for sustained, ongoing control. The duration of therapy is determined by the healthcare professional managing the condition.

Q: What happens if I miss a dose of Imotec?

A: Patient information commonly addresses missed doses by stating that the missed dose should be skipped and the next dose taken at the regularly scheduled time. Taking more than the prescribed amount is strongly advised against, as excessive use may increase the risk of serious adverse effects.

Q: Is it normal to feel a little dizzy when starting Imotec?

A: Official regulatory documents list dizziness as one of the most common adverse effects reported in clinical studies. Dizziness is a known reaction noted in regulatory documents. Concerns about persistent or severe dizziness should be directed to a healthcare professional.

Q: Can Imotec be taken with herbal supplements like St. John's Wort?

A: Regulatory documents list specific interactions with certain drug classes, such as MAO inhibitors, which may potentiate the cardiovascular effects of Imotec. Herbal supplements are not generally named, and the potential for interactions means that the use of herbal products, including St. John's Wort, should be reviewed by a prescribing healthcare professional.

Q: What are the possible interactions with common supplements like multivitamins?

A: The official product label lists interactions with certain medications that can affect blood chemistry, such as diuretics, but does not generally specify interactions with standard multivitamins. Individuals using supplements or vitamins, including multivitamins, are typically directed to inform their healthcare professional to ensure all potential interactions are considered.

Q: Can Imotec be crushed or split?

A: The dry powder capsule formulation of Imotec is designed to be administered using a dedicated inhaler, and regulatory guidance states that it must not be swallowed whole. Since the formulation is not intended to be manipulated for administration, official guidance indicates that the capsule should not be crushed or split before use in the inhalation device.

Q: What should I do if the medicine doesn't seem to be working?

A: Official guidance for similar maintenance treatments indicates that a lack of response may signal a worsening of the underlying condition. If the treatment does not seem to provide the expected effect or if symptoms worsen, a failure of the treatment to provide the expected effect suggests a need for reevaluation by a healthcare professional.

Q: Is Imotec safe to use for people over 65?

A: Studies used in regulatory reviews for Formoterol-containing products included patients 65 years of age and older. No major overall differences in safety or effectiveness were found between this group and younger adult patients. However, consideration of all individual patient factors is necessary when a healthcare professional prescribes any medication.

Q: Is Imotec safe to use during pregnancy?

A: The official documentation states that this drug should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. Beta-agonist drugs may potentially affect uterine function. This factor, among others, requires careful consideration by a healthcare professional.

Q: Can Imotec be used while breastfeeding?

A: Caution is generally advised while breastfeeding. While it is not known if Formoterol is secreted into human milk, it has been found in animal studies. The decision to continue the medication while breastfeeding requires an assessment by a healthcare professional, balancing the potential benefits against the risks.

Q: Why is Imotec sometimes associated with liver function concerns?

A: Official regulatory documents note that Formoterol is metabolized (broken down) in the liver. Consequently, systemic exposure to the drug may increase in patients with severe hepatic impairment (severe liver problems). Close monitoring is recommended for this patient population.

Q: Is Imotec a pain reliever?

A: No, Imotec (Formoterol) is classified as a Long-Acting Beta Agonist (LABA), which is a type of bronchodilator. Its primary function is to relax the muscles around the air passages to provide sustained opening of the airways. It is not indicated or described in official documents as a pain reliever.

Q: Is it true that Imotec is only a short-term treatment?

A: This is inaccurate. Imotec is specifically indicated for long-term, twice-daily use as maintenance therapy for chronic conditions. Official documents state it is not approved for the rapid, short-term relief of sudden or acute breathing problems.

Q: How long does the effect of one dose of Imotec typically last?

A: As a long-acting agent, Imotec is designed to maintain open airways over a sustained period. Official product information indicates that the therapeutic effect of a single dose is sustained for approximately 12 hours.

Q: Does Imotec affect sleep patterns?

A: Yes, official regulatory documents list insomnia (difficulty sleeping) as a common adverse reaction reported in clinical studies. Patients who experience new or worsening sleep issues should inform their healthcare professional.

Q: Does taking Imotec require regular blood tests?

A: Regulatory documents note that the drug can cause minor changes in blood chemistry, specifically lowering potassium (hypokalemia) or raising blood sugar (hyperglycemia). These changes were infrequent in long-term studies at the recommended dose. Routine blood tests are not universally mandated, but a healthcare professional may recommend monitoring for specific patients.

Q: What should I do if I experience an allergic reaction to Imotec?

A: Official labeling states that a known severe allergy (hypersensitivity) to Imotec or its components is a contraindication to use. If symptoms of a severe reaction, such as paradoxical bronchospasm (sudden worsening of breathing), occur, the medicine should be discontinued immediately, and such reactions require the attention of a healthcare professional.

Q: Can Imotec affect my mood or mental state?

A: Yes, the drug belongs to a class of medicines called sympathomimetic amines, which official documentation notes should be used with caution in patients with convulsive disorders. They may also cause CNS (Central Nervous System) stimulation, and insomnia is a common reported side effect.

Q: Is Imotec considered a new or older drug?

A: Formoterol, the active ingredient in Imotec, is a well-established medication that has been approved and marketed internationally for many years. It is widely used in the management of chronic airway conditions.

Q: Can Imotec be used to treat symptoms that are not the main condition?

A: The drug is indicated and approved only for the long-term, twice-daily maintenance treatment of specific airway conditions. Official documents state it is not indicated for the relief of acute symptoms or for any condition outside of its officially approved labeling.

Q: Can Imotec affect the outcome of a laboratory test?

A: Official warnings note that Imotec can affect certain blood levels. Specifically, it can lead to low potassium (hypokalemia) and high blood sugar (hyperglycemia). These potential changes in blood chemistry could impact the outcome of related laboratory tests.

Q: How is Imotec eliminated from the body?

A: Imotec (Formoterol) is metabolized in the liver and then primarily eliminated from the body. Regulatory documents state that the drug and its breakdown products are removed mainly through urinary excretion, with a smaller amount eliminated through feces.

Q: Do I need a special monitoring while on Imotec?

A: The official label advises caution in patients with pre-existing conditions like cardiovascular disorders or severe liver impairment. Patients with severe liver impairment should be monitored closely for signs of increased drug exposure. Specific monitoring requirements are determined by the individual's overall health and underlying condition.

Q: Is Imotec known to cause problems with kidney function?

A: Official documentation for similar medications states that no specific dose adjustment is typically required for patients with kidney (renal) impairment. Imotec is primarily eliminated via the urine, but there is no widely reported association with causing kidney problems in official warnings.

Q: What conditions make someone ineligible to take Imotec?

A: Official contraindications (conditions where the drug must not be used) include a history of severe allergy (hypersensitivity) to the drug or its components. It is also contraindicated for use as a single treatment (monotherapy) in patients with asthma and is intended for use with an inhaled corticosteroid.

Q: Has Imotec been studied in children?

A: Yes, regulatory documents indicate that the dry powder formulation of Imotec is approved for use in children 5 years of age and older. This use covers both the long-term maintenance treatment and the prevention of exercise-induced symptoms, confirming that studies have been conducted in this pediatric population.

How should Imotec be stored and disposed of?

Storage and Disposal of Imotec (Formoterol Fumarate Dihydrate)

Official regulatory labeling defines specific and differing storage conditions for Imotec based on its formulation:

  • Dry Powder for Inhalation: Must be stored at Controlled Room Temperature (20 C to 25 C) and protected from moisture. Storage must remain in the original container and blister package.
  • Nebulizer Solution: Requires refrigerated storage (2 C to 8 C) and must be protected from light and freezing. Once the original foil pouch is opened, the remaining vials must be used within 3 months or discarded.

All forms must be kept out of the sight and reach of children. Unused or expired product must be thrown away and disposed of according to local regulations for pharmaceutical waste.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Imotec found in:

A-Z Index: